
Fairchem OrganicQ2 FY24
Fairchem Organic Q2 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹665.4P/E: 34.2Market Cap: ₹838 Cr
Management growth scorecard
Revenue
Category 3
Margin
Category 1
Fundraise
N/A
Order
N/A
Capex
N/A
1 of 2 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- The company anticipates growth in volumes processed, with Q2 volume processed up 9% quarter-on-quarter.
- Topline growth is linked to raw material prices (refined oil price fluctuating between ₹90-140), making revenue difficult to quantify precisely.
- Capacity utilization is currently around 65%, expected to increase, supporting volume growth.
- New product, isosteric acid, expected to commence commercial shipments in Q3/Q4 FY24, contributing to growth.
- Paint industry seasonality affects quarterly sales; Q2 is traditionally lean.
- Expansion and product development investments are complete; focus now on improving quantities sold and operational efficiency.
- Expects gradual margin improvement to 15%-16% by FY25 due to product mix, capacity utilization, and raw material cost control.
- Long-term revenue growth aligned with growth in the organized paint industry and other diverse applications, especially for dimer acid and isosteric acid products.
See what Fairchem Organic management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no mention of any current or future fundraising through debt or equity in the transcript.
- The company has completed its product development and investments for expansion, indicating no immediate capital requirement.
- Management focuses on improving capacity utilization and product mix rather than seeking new external funding.
- No explicit plans for raising funds via debt or equity were discussed during the call.
See what Fairchem Organic management said on order book — free account, 30 seconds.
Capex plans
- The company has completed major investments related to new product development and plant trials primarily in Q1 and Q2 of FY24.
- Currently, no significant ongoing capital expenditures or investments are indicated; process stabilization is in place.
- Expansion or capacity enhancement is expected mainly through better utilization and scaling up of existing capacities rather than fresh capex.
- Focus is on commercialization and scaling up of the newly developed high-value product, isosteric acid, rather than capital-intensive expansions.
- Future growth is expected to come from improved capacity utilization, product mix, and market expansion, particularly with isosteric acid, rather than fresh large-scale capital investment.
Track Fairchem Organic — get its next earnings analysis in your feed
How does Fairchem Organic rank vs peers in ?
Pro featureThisFairchem Organic
Rev 3Mar 1